What were the dosing regimens of ivermectin in major cancer clinical trials compared with standard antiparasitic doses?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Major clinical testing of ivermectin as an anticancer agent is still sparse: most human data are limited to early-phase trials and registered studies such as NCT05318469 (ivermectin + balstilimab in metastatic triple‑negative breast cancer) with results pending, while most published dosing data come from antiparasitic indications where standard oral doses are 150–200 µg/kg and up to 400 µg/kg for some programs [1] [2] [3]. Preclinical cancer studies often use concentrations and regimens that exceed plasma levels achieved with standard antiparasitic dosing, and human oncology trials so far have not established a standard anticancer dose [4] [5] [6].
1. What “standard” antiparasitic ivermectin dosing looks like
Ivermectin’s established human dosing for parasitic diseases is low‑microgram per kilogram: commonly 150–200 µg/kg for onchocerciasis, strongyloidiasis and enterobiasis, and programs sometimes use 400 µg/kg for lymphatic filariasis campaigns [3] [2]. Those regimens are oral, single‑or few‑dose courses intended to clear parasites; safety and pharmacokinetic data for these doses are well‑characterized in healthy and parasitized patients [3] [2].
2. How cancer research has diverged from antiparasitic regimens
Most cancer work remains preclinical: cell culture and animal studies routinely expose tumor cells to micromolar ivermectin concentrations that are orders of magnitude higher than plasma levels from standard human antiparasitic doses [4] [7]. Reviews and lab papers note that the concentrations producing anticancer effects in vitro often exceed clinically achieved plasma concentrations with standard dosing, raising questions about translatability [4] [2].
3. What early human oncology trials are testing — and what they report about dosing
Human clinical activity in oncology is limited but emerging. ClinicalTrials.gov lists at least one registered trial combining ivermectin with immune checkpoint therapy (NCT05318469) for metastatic triple‑negative breast cancer; the ASCO abstract for a Phase I/II study of ivermectin + balstilimab describes the trial but does not publish full dosing details in the abstract available [1] [8]. Journalistic and patient‑facing outlets report this trial and note it is expected to finish around 2026, but they emphasize that phase‑III evidence is absent [9] [10]. Reviews repeatedly state that clinical trial data remain scarce [6] [2].
4. Reported higher‑dose human exposures outside cancer
Non‑oncology human studies provide some guideposts for higher exposures: a volunteer study escalated ivermectin to 2 mg/kg without serious adverse reactions, and other clinical programs have administered higher or repeated doses (for example, unusual regimens up to 1.6 mg/kg subcutaneously twice weekly in a spinal‑injury study), indicating tolerability in controlled settings but not demonstrating anticancer efficacy [5] [3]. These higher exposures are substantially above the antiparasitic 150–400 µg/kg range [5] [3].
5. The core translational gap: plasma concentration vs. in‑vitro activity
Multiple sources highlight a pharmacologic gap: standard oral dosing yields plasma concentrations (~50 nM cited in one review) far below the micromolar concentrations producing tumor kill in cell lines (e.g., 3 µM in some experiments) — roughly a 100‑fold difference noted in summaries of the evidence [4]. That gap is the central reason why repurposing ivermectin for cancer requires careful dose‑finding studies and pharmacokinetic/pharmacodynamic work rather than simple adoption of antiparasitic regimens [4] [2].
6. Competing perspectives and clinical caution
Some investigators and integrative outlets argue preclinical mechanisms (PAK1, Wnt/β‑catenin, Akt/mTOR and others) justify rapid clinical exploration of ivermectin in oncology [3] [11]. Mainstream clinical reviews and patient‑facing summaries counsel caution: they acknowledge laboratory promise but stress the lack of robust human trials, potential toxicity at very high or veterinary doses, and the ethical risk of patients foregoing proven treatments based on premature claims [6] [10] [4].
7. What’s missing and what to watch for next
Available sources do not give a published, peer‑reviewed Phase II/III oncology dosing regimen that establishes an anticancer standard; they instead point to registered early‑phase trials and preclinical dose discrepancies [1] [5] [4]. The field will pivot on dose‑escalation/safety data and pharmacokinetic bridging from trials such as NCT05318469 and any future published results; until then, standard antiparasitic doses remain distinct from the higher exposures explored in lab cancer models [1] [4] [3].
Limitations: reporting here relies solely on the supplied sources; none offers a completed randomized oncology trial demonstrating efficacy nor a definitive, published anticancer dosing standard for ivermectin [6] [5] [1].